Sanofi's €10bn Dupixent Plan: 'We're Going To Put The JAKs Properly In Their Place'

 
• By Jessica Merrill

Sanofi's new CEO has ambitious forecasts for Dupixent in atopic dermatitis, asthma and other indications. The French pharma outlined how it plans to reach that goal despite new competition vying to get in.

Pop art comic book style super heroine punching with female superhero costume poster design wall decoration illustration
Sanofi is ready to take on oral JAKs • Source: Shutterstock

Sanofi announced an aggressive €10bn peak sales goal for its blockbuster IL-4/IL-13 blocker Dupixent (dupilumab) as the anchor in the company's growth strategy during its Capital Markets Day presentation on 10 December. CEO Paul Hudson outlined how he expects to build Dupixent into a double-digit blockbuster even with the expected eventual entry of oral JAK inhibitors as competitors.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immunological

More from Therapy Areas